Cart
sales@molnova.com
5-phenylthieno[2,3-d]pyrimidin-4-amine
CAS No. 195193-10-3
5-phenylthieno[2,3-d]pyrimidin-4-amine( —— )
Catalog No. M28408 CAS No. 195193-10-3
5-phenylthieno[2,3-d]pyrimidin-4-amine is a chemical compound.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 55 | In Stock |
|
| 2MG | 36 | In Stock |
|
| 5MG | 55 | In Stock |
|
| 10MG | 83 | In Stock |
|
| 25MG | 141 | In Stock |
|
| 50MG | 207 | In Stock |
|
| 100MG | 312 | In Stock |
|
| 200MG | 445 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name5-phenylthieno[2,3-d]pyrimidin-4-amine
-
NoteResearch use only, not for human use.
-
Brief Description5-phenylthieno[2,3-d]pyrimidin-4-amine is a chemical compound.
-
Description5-phenylthieno[2,3-d]pyrimidin-4-amine is a chemical compound.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetALK
-
RecptorRARγ
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number195193-10-3
-
Formula Weight227.285
-
Molecular FormulaC12H9N3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESNc1ncnc2scc(-c3ccccc3)c12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.M I Dawson, et al. Retinoic acid (RA) receptor transcriptional activation correlates with inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase (ODC) activity by retinoids: a potential role for trans-RA-induced ZBP-89 in ODC inhibition. Int J Cancer. 2001 Jan 1;91(1):8-21.
molnova catalog
related products
-
SB-505124 hydrochlor...
SB-505124 hydrochloride (SB505124 hydrochloride) is an orally available, selective and potent inhibitor of TGF-β type I receptors (ALK4, ALK5, ALK7) with IC50 values of 129 nM and 47 nM for ALK4 and ALK5, respectively.
-
ALK2-IN-2
ALK2-IN-2 is a potent and selective inhibitor of activin receptor-like kinase 2 (ALK2) with an IC50 of 9 nM, demonstrating 700-fold higher inhibition of ALK2 compared to ALK3.
-
Zotizalkib
Zotizalkib (TPX-0131) is an orally active and selective ALK inhibitor with antitumor activity for the study of non-small cell lung cancer.
